Article
A potential role for nilotinib in KIT-mutated melanoma.
Expert opinion on investigational drugs - 1 Jun 2012
Tran An, Tawbi Hussein A
Abstract excerpt
INTRODUCTION: The advent of effective immunotherapy and targeted therapy, such as ipilimumab (anti-CTLA-4 monoclonal antibody) and vemurafenib (BRAF inhibitor), are changing the treatment paradigm for metastatic melanoma. One of the most readily recognized targets in metastatic melanoma is the oncogenic 'driver' mutations KIT, which is thought to be an important driver mutation in up to 3% of melanomas. AREAS...
Topics
Join the communities discussing this publication.